Trial Profile
OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Vilobelimab (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors InflaRx
- 20 Mar 2024 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
- 15 Nov 2023 This trial has been discontinued in Belgium and France, according to European Clinical Trials Database record.
- 01 Nov 2023 According to an InflaRx media release, company has decided to stop development in cSCC for the time being and reallocate resources towards the development of the promising orally available C5aR inhibitor, INF904.Patients who are currently still in treatment will be treated for up to 24 months according to the protocol; however, no new patients will be enrolled in the study and clinical sites in which no patients are currently being treated will be closed down.